Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

2021283 citationsJournal Articlehybrid Open Access

Authors

Lihua E. Budde · City Of Hope National Medical Center

Sarit Assouline · Jewish General Hospital

Laurie H. Sehn · University of British Columbia

Stephen J. Schuster · UPMC Hillman Cancer Center

Sung-Soo Yoon · Seoul National University Hospital

Dok Hyun Yoon · Ulsan College

Matthew J. Matasar · Memorial Sloan Kettering Cancer Center

Francesc Bosch

Abstract

Mosunetuzumab, administered with step-up dosing, has a manageable safety profile and induces durable complete responses in R/R B-NHL. The expansion stage of the study is ongoing at the dose level of 1/2/60/60/30 mg selected for further study.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Lymphoma Diagnosis and Treatment

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 5, pp. 481-491

DOI: 10.1200/jco.21.00931

Field-Weighted Citation Impact: 29.96

Command Palette

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Authors

Abstract

Topics & Keywords

Publication Details